VEA
ALLO icon

Virtus ETF Advisers’s Allogene Therapeutics ALLO Stock Holding History

Virtus ETF Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,194
Closed -$75K – 431
2024
Q4 		$75K Sell
35,194
-1,091
-3% -$2.69K 0.03% 348
2024
Q3 		$102K Buy
36,285
+645
+2% +$1.72K 0.05% 374
2024
Q2 		$83K Buy
35,640
+3,673
+11% +$10.8K 0.04% 390
2024
Q1 		$143K Sell
31,967
-2,196
-6% -$9.16K 0.08% 334
2023
Q4 		$110K Buy
34,163
+14,328
+72% +$40.6K 0.07% 331
2023
Q3 		$62.9K Sell
19,835
-1,978
-9% -$8.67K 0.04% 400
2023
Q2 		$108K Buy
21,813
+8,742
+67% +$47.3K 0.06% 348
2023
Q1 		$64.6K Sell
13,071
-5,026
-28% -$32.2K 0.04% 414
2022
Q4 		$114K Buy
18,097
+6,635
+58% +$61.4K 0.06% 431
2022
Q3 		$124K Buy
11,462
+79
+0.7% +$1.07K 0.05% 388
2022
Q2 		$130K Buy
11,383
+535
+5% +$4.75K 0.05% 350
2022
Q1 		$99K Sell
10,848
-639
-6% -$6.66K 0.04% 304
2021
Q4 		$171K Buy
11,487
+3,108
+37% +$54.8K 0.06% 277
2021
Q3 		$215K Sell
8,379
-438
-5% -$10.4K 0.09% 250
2021
Q2 		$230K Sell
8,817
-1,904
-18% -$54.3K 0.09% 241
2021
Q1 		$378K Buy
10,721
+185
+2% +$6.24K 0.16% 192
2020
Q4 		$266K Buy
10,536
+2,925
+38% +$95.3K 0.11% 287
2020
Q3 		$287K Sell
7,611
-1,039
-12% -$39.2K 0.15% 233
2020
Q2 		$370K Sell
8,650
-4,629
-35% -$167K 0.18% 236
2020
Q1 		$258K Sell
13,279
-1,935
-13% -$46.1K 0.11% 245
2019
Q4 		$395K Buy
15,214
+5,662
+59% +$156K 0.06% 260
2019
Q3 		$260K Sell
9,552
-532
-5% -$15.2K 0.05% 213
2019
Q2 		$271K Buy
+10,084
New +$281K 0.06% 258

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's ALLO Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 35,194 shares — an estimated $75K sold.

Virtus ETF Advisers first reported a position in ALLO in Q2 2019 and held it in 23 quarters. The position peaked at $395K in Q4 2019. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 35,194 Allogene Therapeutics shares in Q1 2025, an estimated $75K.
  • Virtus ETF Advisers first reported a position in Allogene Therapeutics in Q2 2019 and held it in 23 quarters.
  • Virtus ETF Advisers's Allogene Therapeutics position peaked at $395K in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.